Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2026)

Top biotech stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Immucell (NASDAQ:ICCC) is the #1 top biotech stock out of 606 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Immucell (NASDAQ:ICCC) is: Value: C, Growth: A, Momentum: B, Sentiment: C, Safety: C, Financials: B, and AI: B.

Immucell (NASDAQ:ICCC) has a Due Diligence Score of 19, which is -5 points lower than the biotech industry average of 24. Although this number is below the industry average, our proven quant model rates ICCC as a "A".

ICCC passed 6 out of 33 due diligence checks and has weak fundamentals. Immucell has seen its stock return 77.26% over the past year, overperforming other biotech stocks by 90 percentage points.

Corcept Therapeutics (NASDAQ:CORT) is the #2 top biotech stock out of 606 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Corcept Therapeutics (NASDAQ:CORT) is: Value: B, Growth: A, Momentum: B, Sentiment: B, Safety: C, Financials: B, and AI: C.

Corcept Therapeutics (NASDAQ:CORT) has a Due Diligence Score of 50, which is 26 points higher than the biotech industry average of 24.

CORT passed 17 out of 33 due diligence checks and has strong fundamentals. Corcept Therapeutics has seen its stock return 52.99% over the past year, overperforming other biotech stocks by 66 percentage points.

Corcept Therapeutics has an average 1 year price target of $122.60, an upside of 11.66% from Corcept Therapeutics's current stock price of $109.80.

Corcept Therapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Corcept Therapeutics, 60% have issued a Strong Buy rating, 20% have issued a Buy, 0% have issued a hold, while 20% have issued a Sell rating, and 0% have issued a Strong Sell.

Xeris Biopharma Holdings (NASDAQ:XERS) is the #3 top biotech stock out of 606 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Xeris Biopharma Holdings (NASDAQ:XERS) is: Value: B, Growth: B, Momentum: C, Sentiment: C, Safety: C, Financials: B, and AI: C.

Xeris Biopharma Holdings (NASDAQ:XERS) has a Due Diligence Score of 42, which is 18 points higher than the biotech industry average of 24.

XERS passed 15 out of 33 due diligence checks and has strong fundamentals. Xeris Biopharma Holdings has seen its stock return 47.3% over the past year, overperforming other biotech stocks by 60 percentage points.

Xeris Biopharma Holdings has an average 1 year price target of $10.00, an upside of 22.1% from Xeris Biopharma Holdings's current stock price of $8.19.

Xeris Biopharma Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Xeris Biopharma Holdings, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 7 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Yarrow Bioscience (NASDAQ:YARW) has an annual dividend yield of 52.95%, which is 40 percentage points higher than the biotech industry average of 12.75%.

Yarrow Bioscience's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 38.09%, which is 25 percentage points higher than the biotech industry average of 12.75%.

Dominari Holdings's dividend payout ratio of -19.1% indicates that its high dividend yield might not be sustainable for the long-term.

Oramed Pharmaceuticals (NASDAQ:ORMP) has an annual dividend yield of 5.61%, which is -7 percentage points lower than the biotech industry average of 12.75%.

Oramed Pharmaceuticals's dividend payout ratio of 9.4% indicates that its high dividend yield is sustainable for the long-term.

Biotech stocks were up 2.63% in the last day, and up 0.44% over the last week. Ensysce Biosciences was the among the top gainers in the biotechnology industry, gaining 37.14% yesterday.

Ensysce Biosciences shares are trading higher after the company received a U.S. patent notice titled "compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof."

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Cormedix (NASDAQ:CRMD) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Cormedix has a valuation score of 43, which is 31 points higher than the biotech industry average of 12. It passed 3 out of 7 valuation due diligence checks.

Cormedix's stock has dropped -39.21% in the past year. It has underperformed other stocks in the biotech industry by -26 percentage points.

Innoviva (NASDAQ:INVA) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Innoviva has a valuation score of 43, which is 31 points higher than the biotech industry average of 12. It passed 3 out of 7 valuation due diligence checks.

Innoviva's stock has gained 12.21% in the past year. It has overperformed other stocks in the biotech industry by 25 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 29, which is 17 points higher than the biotech industry average of 12. It passed 2 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 9.12% in the past year. It has overperformed other stocks in the biotech industry by 22 percentage points.

70.93% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 55.03% over the next year.

3.05% of biotech stocks have a Zen Rating of A (Strong Buy), 4.14% of biotech stocks are rated B (Buy), 40.74% are rated C (Hold), 40.96% are rated D (Sell), and 11.11% are rated F (Strong Sell).